Minerva Neurosciences, Inc. - Special Call Transcript
Greetings, and welcome to the management call to discuss results from Phase III trial of roluperidone hosted by Minerva Neurosciences. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the call over to your host. Mr. Bill Boni, Director of Investor Relations at Minerva Neurosciences.
Good morning, and welcome. This is Bill Boni, VP of Investor Relations at Minerva. Welcome to the company's June 5, 2020 conference call to discuss additional analysis from the Phase III trial of roluperidone to treat negative symptoms in schizophrenia. Top line results from this trial were announced on May 29, 2020.
The Minerva management team, led by Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer; is joined today by key opinion leaders, Dr. Phil Harvey; and Dr. Brian Kirkpatrick. Dr. Harvey is Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami, Miller
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |